Search Within

Michael Andrew Postow

  1. "Biostatistics Service"
Formats
  1. Journal Article (46)
  2. Meeting Abstract (30)
  3. Research Letter (2)
Groups
  1. Biostatistics Service (78)
  2. Department of Medicine (78)
  3. Epidemiology and Biostatistics (78)
  4. Melanoma Disease Management Team (78)
  5. Melanoma and Immunotherapeutics Service (78)
  6. Solid Tumor Oncology Division (78)

More Groups

People
  1. Katherine Panageas (64)
  2. Jedd Wolchok (45)
  3. Alexander Shoushtari (35)
  4. Margaret Callahan (33)
  5. Paul Chapman (31)
  6. Parisa Momtaz (25)

More People

Years
  1. 2025 (4)
  2. 2024 (5)
  3. 2023 (7)
  4. 2022 (8)
  5. 2021 (8)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (28)
  2. Annals of Surgical Oncology (5)
  3. Journal for ImmunoTherapy of Cancer (5)
  4. The Oncologist (5)
  5. Clinical Cancer Research (4)
  6. JAMA Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (28)
  2. American Association for Cancer Research (6)
  3. Oxford University Press (6)
  4. Biomed Central Ltd (5)
  5. Nature Publishing Group (5)
  6. Springer (5)

More Publishers

Results (78)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management and outcomes of clostridioides difficile infection in patients on immune checkpoint inhibitors
    Journal Article

    Magahis, P. T.; Satish, D.; Kamboj, M.; Babady, N. E.; Baul, J.; Kalvin, H. L.; Panageas, K.; Postow, M. A.; Laszkowska, M.; Faleck, D. M.
    Journal of the National Comprehensive Cancer Network (2025)

    Fulltext@MSK | Save
  • Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma
    Journal Article

    Smithy, J. W.; Peng, X.; Ehrich, F. D.; Moy, A. P.; Yosofvand, M.; Maher, C.; Aleynick, N.; Vanguri, R.; Zhuang, M.; Lee, J.; more...
    Cell Reports (2025)

    Fulltext@MSK | Save
  • Intracranial outcomes of ipilimumab and nivolumab in melanoma brain metastases after progression on anti-PD-1 therapy
    Research Letter

    Lochrin, S. E.; Kalvin, H. L.; Smithy, J. W.; Chen, M. F.; Momtaz, P.; Shoushtari, A. N.; Panageas, K. S.; Postow, M. A.
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment
    Journal Article

    Mao, J. J.; Bryl, K.; Gillespie, E. F.; Green, A.; Hung, T. K. W.; Baser, R.; Panageas, K.; Postow, M. A.; Daly, B.
    npj Digital Medicine (2025)

    Fulltext@MSK | Save
  • A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
    Meeting Abstract

    Warner, A. B.; Smithy, J. W.; Postow, M. A.; Panageas, K.; Schoenfeld, A. J.; Wolchok, J. D.; Shoushtari, A. N.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma
    Meeting Abstract

    Smithy, J. W.; Momtaz, P.; Shoushtari, A. N.; Das, J. P.; Lezcano, C.; Nair, S.; Lochrin, S. E.; Chen, M. F.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy
    Meeting Abstract

    Lochrin, S. E.; Kalvin, H. L.; Smithy, J. W.; Momtaz, P.; Shoushtari, A. N.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment
    Meeting Abstract

    Daly, R. M.; Bryl, K.; Baser, R. E.; Green, A.; Hung, T.; Gillespie, E. F.; Panageas, K.; Postow, M. A.; Mao, J. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Early on-treatment assessment of T cells, cytokines, and tumor DNA with adaptively dosed nivolumab + ipilimumab: Final results from the phase 2 ADAPT-IT study
    Journal Article

    Smithy, J. W.; Kalvin, H. L.; Ehrich, F. D.; Shah, R.; Adamow, M.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Exocrine pancreatic insufficiency induced by immune checkpoint inhibitors
    Journal Article

    Satish, D.; Lin, I. H.; Flory, J.; Gerdes, H.; Postow, M. A.; Faleck, D. M.
    The Oncologist (2023)

    Fulltext@MSK | Save